缪丽燕

缪丽燕.jpg


姓名:缪丽燕

技术职称:教授

导师类别:博士生导师

所在学科:药剂学

Emailmiaolysuzhou@163.com

 

简介:

缪丽燕,教授,主任药师,博士生导师,苏州大学附属第一医院副院长,药物临床试验机构办主任、临床药学教研室主任,苏州大学药学院临床药学系主任。兼具临床和药学背景,专业主攻方向为个体化药物治疗与合理用药,尤其在基于生理病理和遗传因素的个体化给药模型、群体药动学药效学模型及药物安全性、有效性研究等方面取得了很有临床意义的研究成果,为临床药物的选择以及个体化给药方案提供依据。同时,作为卫生部国际合理用药网络(INRUD)中国中心组个体化药物治疗组组长单位负责人,组织各网络医院开展多中心的基因多态性与个体化药物治疗相关研究。


学习、工作经历:

1984.9-1989.7 苏州医学院医学系本科  学士学位

1989.9-1992.7 广州中山医科大学药理系硕士学位

1995.9-1998.7 苏州医学院附属第一医院心血管内科博士学位

1998.7-1999.9苏州医学院附属第一医院心血管内科实验室

1999.7-2002.7 美国密西西比医学中心博士后

2002.7-至今  苏州大学附属第一医院药剂科、国家药物临床试验机构、副院长

2005.3-2006.9 清华大学国际创新管理(医院药事管理)研究生课程进修班

 

主要研究方向

1. 个体化药物治疗与合理用药;

2. 临床药理学研究;

3. 临床药物代谢动力学研究;

4. 药事管理。

 

科研项目(2010年至今):

1. 《基于同位素示踪技术的抗肿瘤药物临床评价技术平台的建设》,国家新药创制重大专项,1698.87万。主持

2. FXR-胆汁酸介导的吡嗪酰胺肝毒性新机制及临床意义》,国家自然科学基金(面上),2017,55万。主持

3. 《新型循环肿瘤DNA基因突变检测技术平台的研发及其在临床肿瘤靶向治疗中应用评价》,江苏省科技厅临床医学科技专项,2015.1-2017.1250万。主持

4. 《多中心PIVAS集中调配人员抗肿瘤药物职业暴露的评估》,卫生部医院管理研究所,2013.11-2015.1160万。主持

5. 《新颖的RhoA蛋白GTP结合域竞争性小分子抑制剂的设计与合成及其抑制血管痉挛活性研究》,国家自然科学基金,2012.10,编号8120239423万。第二

6. 《基本药物制度下药物安全使用的研究》江苏省六大人才高峰资助项目,2012.16万。主持

7. 《即时临床基因分型检测与临床个体化用药研究》江苏省卫生厅医学重点人才资助项目,2011.10,编号RC2011110110万。主持

8. CES1A2基因多态性与PCI术患者氯吡格雷代谢及抗血小板活性相关性研究》国家自然科学基金 2011。主持

9. 《基本药物制度下药物合理使用的评价与研究》苏州市科技项目 应用基础研究 医疗卫生重点项目 2010-2012SYS20100150万。主持

10. HCE1启动子基因多态性与氯吡格雷抗血小板活性相关性研究》省卫生厅2010-2012年,6万。主持

 

获奖情况(近五年):

1. 2016.12,江苏省科学技术奖三等奖,血管狭窄性疾病干预的创新与应用。

2. 2016.2,江苏省卫生计生委十二五科教兴卫工程优秀重点学科和人才表彰中授予优秀医学重点人才称号。

3. 2015.8,江苏省医学新技术引进奖二等奖,非线性混合效应模型建模技术用于造血干细胞移植患者免疫抑制剂临床个体化药物治疗。

4. 2015.4,江苏医学科技奖三等奖,个体化治疗技术与服务平台的建立及其在临床合理用药中的应用评价。

5. 2015,苏州市科技进步奖三等奖,新颖的RhoA蛋白小分子抑制剂的研制及其药理活性研究。

6. 2011年江苏省六大人才高峰培养对象。

7. 2012年江苏省新技术引进奖二等奖,即时基因检测技术在华法林临床个体化给药中的应用研究。


学术任职:

中国药学会医院药学专业委员会委员、中国研究型医院学会药物评价专业委员会副主委、中国医院协会药事管理专业委员会副主委、中国药理学会治疗药物监测研究专业委员会副主委、江苏省医学会临床药学专业委员会候任主委、江苏省药学会医院药学专业委员会副主任委员、江苏省医院协会药事管理专业委员会副主委、INRUD/中国中心组个体化药物治疗组组长。

 

杂志编委:

《中国药房》副主编、《医学科学报药学专刊》副主编、《中国医院用药评价与分析》副主编、《药物不良反应杂志》编委、《中国临床药学杂志》编委、《药学与临床研究杂志》编委、《中国医院药学杂志》编委等。

 

代表文章:

1. Zubcov AMiao L et al. Signal Transduction of ET-1 in Contraction of Cerebral Arteries.
J Cardiovasc Pharmacol. 2004 Nov; 44 Suppl 1:S24-6.

2. Sung JKMiao L et al A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat.Brain Res. 2003 Jan 3; 959(1):29-38.

3. Massey ARMiao L et al.  Increased RhoA translocation in renal cortex of diabetic rats.
Life Sci. 2003 May 16; 72(26):2943-52.

4. L.MiaoJ. W. CalvertJ. TangJ. H. Zhang. Upregulation of Small GTPase RhoA in the Basilar Artery from Diabetic (mellitus) Rats. Life Science 2002. 71(10):1175-1185

5. L.MiaoY. DaiJ. H. Zhang. Mechanism of RhoA/ROK kinase activation in endothelin-1-induced contraction in rabbit basilar artery.    Am.J. Physiol Heart Circ 2002 283(3):H983-H989.

6. L. MiaoJ. CalvertJ. TangA. Parent & J. Zhang. Age-related Rho-A expression in Blood Vessels of Rats. Mechanism of Aging and Development 122: 1757-17702001.

7. L. MiaoJ. TangD. Esposito & J. Zhang. Age-related Changes of P2 Receptor mRNAs of Rat Cerebral Arteries. Experimental Gerontology 37: 67-79, 2001.

8. R. CarpenterL. MiaoYMiyagiE. Bengten & J. Zhang. Altered Expression of P(2) Receptor mRNAs in the Basilar Artery in a Rat Double Hemorrhage Model.  Stroke 32: 516-522, 2001.

9. Miao L Yang J Huang C Shen Z  Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41.

10. Huang CRYang JDu YHMiao LY*. Measurement of Free Concentrations of Highly Protein-Bound Warfarin in Plasma by Ultra Performance Liquid Chromatography –Tandem Mass Spectrometry and its Correlation with the International Normalized Ratio. Clin Chim Acta2008393: 85-89.

11. Miao LY  Huang CR Hou JQ Qian MY  Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipientsBiopharm Drug Dispos. 2008 Jan;29(1):1-5.

12. Ling XueJian-Zhong RuiYan Zhangand Li-Yan Miao* Population Pharmacokinetics Study of Tacrolimus in Chinese Hematopoietic Cell Transplant Patients. Blood  Nov 2009; 114: 4668.

13. J. YangC. HuangZ. Shen and L. Miao  Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation International Journal of Clinical Pharmacology and TherapeuticsVol. 49 – No. 1/2011 (23-29).

14. Yan Zhang Jin WangLi-Mei ZhaoWei Peng Guo-Qing Shen Ling Xue Xiao-Xian Zheng Xiao-Jing HE Chun-Yan GongLi-Yan Mia.o*Strong association between HLA-B*1502and carbamazepine-induced Stevens-Johnson syndromeand toxic epidermal necrolysis in mainland Han Chinese patients Eur J Clin Pharmacol. 2011 Sep;67(9):885-7.

15. Jing DengEnguang FengSheng MaYan ZhangXiaofeng LiuHonglin LiHuang HuangJin ZhuWeiliang ZhuXu ShenLiyan Miao*Hong LiuHualiang Jiangand Jian Li*  Design and Synthesis of Small Molecule RhoA Inhibitors:A New Promising Therapy for Cardiovascular Diseases?  Journal of Medicinal Chemistry  2011544508–4522.

16. Ling XueHua ZhangSheng MaJian-Zhong RuiLi-Yan Miao*Population Pharmacokinetics and Pharmacogenetics of tacrolimus in Healthy Chinese VolunteersPharmacology 2011;88:288–294.

17. Xiao-Liang Ding,Yang-Lin Deng,Jun Zhang,Li-Yan Miao*Mutation-Sensitive Molecular Switch Method to Detect CES1A2 Mutation in the Chinese Han and Yao PopulationsGENETIC TESTING AND MOLECULAR BIOMARKERSVolume 15, Number 9, 2011.

18. Chenrong Huang, Jie Gao, Liyan Miao*Simultaneous determination of flucloxacillin and ampicillin in human plasma by ultra performance liquid chromatography–tandem mass spectrometry and subsequent application to a clinical study in healthy Chinese volunteersJournal of Pharmaceutical and Biomedical Analysis 59 (2012) 157–161.

19. Zhang JJ, Zhang H, Ding XL, Ma S, Miao LY*  Effect of the P450 oxidoreductase*28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteer.  Eur J Clin Pharmacol. 2013 Apr;69(4):807-12.

20. Yan Zhang, Jing Deng, Sheng Ma, Lin Xue, Jin Zhu, Wei-liang Zhu, Hua-liang Jiang, Jian Li, and Li-yan Miao*The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery ContractionCurrent Pharmaceutical Design, 2012, 18, 4258-4264.

21. DingXiaoliang,JiangBin,Gaojie,Zhanglingli,Zhanghua,Zhangjingjing,Miaoliyan,Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation- An update meta-analysis of randomized controlled trials, Journal of Cardiovascular Pharmacology and Therapeutics, 2013 May;18(3):222-8.

22. Dong J, Jiang D, Wang Z, Wu G, Miao L*, Huang L. Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model. Int J Pharm. 2013 Jan 30; 441(1-2):285-90.

23. Rong Chen, Jie Li , Wen‑wei Hu , Ming‑li Wang ,Su‑lan Zou , Li‑yan Miao*,Circadian variability of pharmacokinetics of cisplatin in patients with non‑small‑cell lung carcinoma: analysis with the NONMEM program, Cancer Chemother Pharmacol (2013) 72:1111–1123.

24. Ji Dong, Shuaibing Liu, Hua Zhang, Qianli Hua, Xuegang Zhao, Liyan Miao∗,Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS.  Journal of Chromatography B, 942–943 (2013) 83-87.

25. Cheng Xie, Xiaoliang Ding, Jie Gao, Yongfu Hang,Hua Zhang, Jingjing Zhang, Bin Jiang and Liyan Miao*. The effects of CES1A2 A(-816)C and CYP2C19 loss-offunction polymorphisms on clopidogrel response variability among Chinese patients with coronary heart diseasePharmacogenetics and Genomics 2014, Vol 24 No 4204-210.

26. Xue L1, Zhang WW, Ding XL, Zhang JJ, Bao JA, Miao LY.*, Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients. Am J Med Sci. 2014 Dec; 348(6):448-54.

27. Chenrong Huang, Wei Wang, Liyan Miao. Determination of Cefaclor by UPLC-MS/MS for a Chinese pharmacokinetic study. Journal of Chromatographic Science, J Chromatogr Sci. 2014 Aug; 52(7):636-40.

28. Chen ZY, Zhang SC, Zhang JJ, Zhang Y, Xue L, Miao LY*, Rs9263726 is a specific genetic marker for allopurinol-induced severe cutaneous adverse reactions in Chinese patients. Per.Med. 2015.11 2015 12(6)591–600.

29. Ma S, Deng J, Li B, Li X, Yan Z, Zhu J, Chen G, Wang Z, Jiang H, Miao L*, Li J*,Development of Second-Generation Small Molecular RhoA Inhibitors with Enhanced Water Solubility, Tissue Potency and Significant in Vivo Efficacy. Chem Med Chem, 2015.1,2015 Jan;10(1):193-206.

30. Jingjing Zhang, Shuaibin Liu, Ling Xue, Xiaoliang Ding, Hua Zhang, Liyan Miao. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients International Journal of Clinical Pharmacology and Therapeutics. 2015.9, 2015 Sep;53(9):728-36.

31. Rong Chen, Li Zhou, Ji Dong, Liyan Miao*. A rapid and underivatized method for the determination of glutamine in human serum with ultra performance liquid chromatography–tandem mass spectrometry and its application International Journal of Food Sciences and Nutrition 2015.5 2015 May;66(3):243-7.

32. J. Zhang, J. Bao, R. Wang, Z. Geng, Y. Chen, X. Liu, Y. Xie, L. Jiang, Y. Deng, G. Liu, R. Xu, L. Miao, A multicenter study of biological effects assessment of pharmacy workers occupationally exposed to antineoplastic drugs in Pharmacy Intravenous Admixture Services, Journal of hazardous materials, 315 (2016) 86-92.

33. Linsheng Liu, Chenrong huang,Yicong Bian,Liyan MiaoGC-MS based metabolomics of CSF and blood serum: Metabolic phenotype for a rat model of cefoperazone-induced disulfiram-like reaction, Biochem Biophys Res Commun, 2017,490 (3):1066-1073.

34. Xue L, Holford N, Ding XL, Shen ZY, Huang CR, Zhang H, Zhang JJ, Guo ZN, Xie C, Zhou L, Chen ZY, Liu LS, Miao LY, Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients, Br J Clin Pharmacol, 2017,83(4):823-835.

35. Hang Y , Chen Y , Xue L , Sun S , Liu L , Gao J , Xie C , Zhang X , Zhu J , Jin J , Miao L, Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: A pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation, Int J Antimicrob Agents, 2017 Jul 11.